ESMO Breast 2021 | Abemaciclib for HR+/HER2- advanced or metastatic breast cancer

Name: Abemaciclib for HR+/HER2- advanced or metastatic breast cancer
Uploaded: 2021-05-06T00:00:00Z
Duration: 1 min 39 s
Description: Ahmad Awada, MD, PhD, Institute Jules Bordet, Brussels, Belgium, talks on the use of abemaciclib, a CDK 4/6 inhibitor, for the treatment of HR+/HER2- advanced or metastatic breast cancer, highlighting results from the MONARCH 2 trial (NCT02107703). This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.

Ahmad Awada • 6 May 2021

ESMO Breast 2021

Breast Cancer Abemaciclib

MONARCH 2

Ahmad Awada, MD, PhD, Institute Jules Bordet, Brussels, Belgium, talks on the use of abemaciclib, a CDK 4/6 inhibitor, for the treatment of HR+/HER2- advanced or metastatic breast cancer, highlighting results from the MONARCH 2 trial (NCT02107703). This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.

Disclosures

Ahmad Awada, MD, PhD, has participated in an advisory role, has received institutional research grants, or has received speakers fees from Roche, Lilly, Amgen, EISAI, BMS, Pfizer, Novartis, MSD, Genomic Health, Ipsen, AstraZeneca, Bayer, Leo Pharma, Merck and Daiichi.